» Articles » PMID: 20332231

Antitumor Activity of Hyaluronic Acid Synthesis Inhibitor 4-methylumbelliferone in Prostate Cancer Cells

Overview
Journal Cancer Res
Specialty Oncology
Date 2010 Mar 25
PMID 20332231
Citations 104
Authors
Affiliations
Soon will be listed here.
Abstract

4-Methylumbelliferone (4-MU) is a hyaluronic acid (HA) synthesis inhibitor with anticancer properties; the mechanism of its anticancer effects is unknown. We evaluated the effects of 4-MU on prostate cancer cells. 4-MU inhibited proliferation, motility, and invasion of DU145, PC3-ML, LNCaP, C4-2B, and/or LAPC-4 cells. At IC(50) for HA synthesis (0.4 mmol/L), 4-MU induced >3-fold apoptosis in prostate cancer cells, which could be prevented by the addition of HA. 4-MU induced caspase-8, caspase-9, and caspase-3 activation, PARP cleavage, upregulation of Fas-L, Fas, FADD and DR4, and downregulation of bcl-2, phosphorylated bad, bcl-XL, phosphorylated Akt, phosphorylated IKB, phosphorylated ErbB2, and phosphorylated epidermal growth factor receptor. At IC(50), 4-MU also caused >90% inhibition of NF-kappaB reporter activity, which was prevented partially by the addition of HA. With the exception of caveolin-1, HA reversed the 4-MU-induced downregulation of HA receptors (CD44 and RHAMM), matrix-degrading enzymes (MMP-2 and MMP-9), interleukin-8, and chemokine receptors (CXCR1, CXCR4, and CXCR7) at the protein and mRNA levels. Expression of myristoylated-Akt rescued 4-MU-induced apoptosis and inhibition of cell growth and interleukin-8, RHAMM, HAS2, CD44, and MMP-9 expression. Oral administration of 4-MU significantly decreased PC3-ML tumor growth (>3-fold) when treatment was started either on the day of tumor cell injection or after the tumors became palpable, without organ toxicity, changes in serum chemistry, or body weight. Tumors from 4-MU-treated animals showed reduced microvessel density ( approximately 3-fold) and HA expression but increased terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling-positive cells and expression of apoptosis-related molecules. Therefore, the anticancer effects of 4-MU, an orally bioavailable and relatively nontoxic agent, are primarily mediated by inhibition of HA signaling.

Citing Articles

Extraction efficiency and bioactive evaluation of Tamarix nilotica and Arthrocnemum macrostachyum extracts for anti-cancer potential.

Al Kaabi M, ElNaker N, Jan N, Ochsenkuhn M, Amin S, Yousef L PLoS One. 2025; 20(1):e0311567.

PMID: 39836644 PMC: 11750082. DOI: 10.1371/journal.pone.0311567.


Mendelian randomization reveals potential causal relationships between cellular senescence-related genes and multiple cancer risks.

Qiu X, Guo R, Wang Y, Zheng S, Wang B, Gong Y Commun Biol. 2024; 7(1):1069.

PMID: 39215079 PMC: 11364673. DOI: 10.1038/s42003-024-06755-9.


Glycooligomer-Functionalized Catalytic Nanocompartments Co-Loaded with Enzymes Support Parallel Reactions and Promote Cell Internalization.

Korpidou M, Becker J, Tarvirdipour S, Dinu I, Becer C, Palivan C Biomacromolecules. 2024; 25(7):4492-4509.

PMID: 38910355 PMC: 11238334. DOI: 10.1021/acs.biomac.4c00526.


Teaching an Old Drug a New Trick: Targeting Treatment Resistance in Genitourinary Cancers.

Aguilar K, Sharma A, Yang T, Mehta D, Panda C, Lokeshwar V J Cell Signal. 2024; 5(2):51-56.

PMID: 38726221 PMC: 11081427. DOI: 10.33696/signaling.5.112.


Hyaluronic acid metabolism and chemotherapy resistance: recent advances and therapeutic potential.

Liu Z, Hou P, Fang J, Shao C, Shi Y, Melino G Mol Oncol. 2023; 18(9):2087-2106.

PMID: 37953485 PMC: 11467803. DOI: 10.1002/1878-0261.13551.


References
1.
Morohashi H, Kon A, Nakai M, Yamaguchi M, Kakizaki I, Yoshihara S . Study of hyaluronan synthase inhibitor, 4-methylumbelliferone derivatives on human pancreatic cancer cell (KP1-NL). Biochem Biophys Res Commun. 2006; 345(4):1454-9. DOI: 10.1016/j.bbrc.2006.05.037. View

2.
Kudo D, Kon A, Yoshihara S, Kakizaki I, Sasaki M, Endo M . Effect of a hyaluronan synthase suppressor, 4-methylumbelliferone, on B16F-10 melanoma cell adhesion and locomotion. Biochem Biophys Res Commun. 2004; 321(4):783-7. DOI: 10.1016/j.bbrc.2004.07.041. View

3.
Lokeshwar V, Cerwinka W, Isoyama T, Lokeshwar B . HYAL1 hyaluronidase in prostate cancer: a tumor promoter and suppressor. Cancer Res. 2005; 65(17):7782-9. DOI: 10.1158/0008-5472.CAN-05-1022. View

4.
Golshani R, Lopez L, Estrella V, Kramer M, Iida N, Lokeshwar V . Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44. Cancer Res. 2008; 68(2):483-91. DOI: 10.1158/0008-5472.CAN-07-2140. View

5.
Simpson M, Lokeshwar V . Hyaluronan and hyaluronidase in genitourinary tumors. Front Biosci. 2008; 13:5664-80. PMC: 2630716. DOI: 10.2741/3108. View